Proxy advisory firm ISS advised against CoreWeave’s $9 billion acquisition of Core Scientific, suggesting the latter can thrive independently. Two Seas Capital opposed the deal due to concerns about the sale process and stock valuation, as CoreWeave’s shares have declined, reducing the deal’s value. Core Scientific’s stock rose 5% post-hours, indicating investor preference for independence.

Read more at Yahoo Finance: ISS recommends investors reject CoreWeave deal for Core Scientific